The lack of effective disease-modifying treatments in SLE and the evidence of the role of CD38 positive cells in SLE pathogenesis might, therefore, encourage the use of therapies that effectively deplete antibody-producing plasma cells. The gene discussed is CD38; the disease is systemic lupus erythematosus.